BioCryst to present new real-world evidence showing significant reductions in medical visits and hospitalizations after starting Orladeyo (berotralstat)

BioCryst Pharmaceuticals announced new real-world evidence on the use of oral, once-daily Orladeyo (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU), including significant reductions in hospitalizations, emergency room visits and use of on-demand therapies, after beginning treatment with Orladeyo.

The study will be presented in a poster at the Academy of Managed Care Pharmacy (AMCP) Nexus 2024 national meeting, which is being held in Las Vegas from 14-17 October 2024.

Professor Sandra Christiansen MD, Professor of Medicine and Director of Translational Research at the US HAEA Angioedema Center at the University of California, San Diego, said: “Our interrogation of claims data builds upon previously reported findings demonstrating that Orladeyo not only has a favorable impact on the lives of patients with HAE – but the broader healthcare system, as well.

“Here, our analysis reveals that significant reductions in healthcare resource utilization are achieved across multiple outcomes – such as reductions in hospitalizations and medical visits, including those related to HAE attacks. Decreases in on-demand treatment were also observed. Taken together, our investigation provides promising real-world evidence which supports Orladeyo’s clinical and financial value as a prophylactic therapy for HAE.”

(Source: BioCryst)